Atlas Trials

Endometrial Mixed Cell Adenocarcinoma

10 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Endometrial Mixed Cell Adenocarcinoma

RecordFirmDate
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (NCT05112601)National Cancer Institute (NCI)2022-06-02
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer (NCT03914612)National Cancer Institute (NCI)2019-08-22
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone (NCT03660826)National Cancer Institute (NCI)2018-09-27
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer (NCT02728258)NRG Oncology2016-09-16
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers (NCT02020707)Mayo Clinic2014-02-24
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT01935973)National Cancer Institute (NCI)2013-09-30
Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer (NCT01935934)National Cancer Institute (NCI)2013-05-08

Track Endometrial Mixed Cell Adenocarcinoma automatically

Every clearance here is in the API, with alerts when new ones post.